Astellas

Contact
astellas.ca
+1905-470-7990

Astellas Pharma Canada, Inc.

675 Cochrane Drive Suite 500 West Tower
L3R 0B8 Markham
Canada
+1905-470-7990
astellas.ca
Contact
Profile News
Contact

About Astellas

Astellas Pharma Canada, Inc., a Canadian affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to improving the health of people around the world through innovative and reliable pharmaceutical products. Astellas was formed in 2005 through the merger of two companies - Fujisawa and Yamanouchi. Astellas Pharma Canada has an intense focus on five key therapeutic areas - Infectious Disease, Immunology, Cardiology, Urology and Dermatology - and is considered a leader in these fields.

Read more about Astellas
Facts about Astellas
  • Focus : Manufacturer
  • Employees: 51-200
  • Industry : Pharma

News about Astellas

Astellas

30-Oct-2014 | business & finance

QIAGEN announces broad agreement with Astellas Pharma to develop companion diagnostics

First two programs aim to create tests to aid in cancer treatment with Astellas compounds under development

Read news
Astellas

04-Jan-2013 | research and development

Astellas and UCB announce approval of Cimzia in Japan for the treatment of rheumatoid arthritis

Astellas Pharma Inc. and UCB S.A. announced that UCB Japan has received marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) ...

Read news
Astellas

10-Sep-2012 | business & finance

Abbott to Collaborate with Astellas in CMV Vaccine Trial

Abbott announced that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVax ...

Read news
Astellas

04-Mar-2011 | business & finance

MediGene Completes the Transfer of Eligard Rights for EU Countries to Astellas

MediGene AG  announced that exclusive European rights to the cancer drug Eligard® have been transferred to Astellas Pharma Europe Ltd., with effect from ...

Read news
Astellas

29-Nov-2010 | research and development

Basilea and Astellas update isavuconazole phase III trial in consultation with FDA

Basilea Pharmaceutica Ltd. announced that in consultation with the U.S. Food and Drug Administration (FDA) Basilea and its partner Astellas Pharma Inc. ...

Read news
Astellas

21-Jul-2010 | business & finance

MediGene sells full European rights for Eligard® to Astellas for EUR 25 million and ongoing royalties

MediGene AG announces the sale of full European marketing and distribution rights to Eligard® (leuprolide acetate, for the treatment of hormone-dependent ...

Read news
Astellas

01-Jul-2010 | people

Astellas Pharma Canada Appoints New President

Astellas Pharma Canada, Inc. announced that Michael Tremblay has been appointed president of the Canadian subsidiary of Astellas Pharma Inc. His ...

Read news
Astellas

29-Jun-2010 | research and development

Basilea provides update on phase III program for the antifungal isavuconazole

Basilea Pharmaceutica Ltd. announced that its partner Astellas Pharma Inc.has initiated the formal process to allow continuation of patient recruitment ...

Read news
Show more news about Astellas

Here you will find Astellas Pharma Canada, Inc.